Abstract
Clarithromycin was administered to nine previously untreated lepromatous leprosy patients. Patients received two 1,500-mg doses on the first day, followed by 7 days of no treatment, in order to evaluate the potential efficacy of intermittent therapy. Patients then received 1,000 mg daily for 2 weeks followed by 500 mg daily for 9 weeks. The efficacy of therapy was monitored clinically, by changes in morphological index, mouse footpad infectivity, and radiorespirometric activity of Mycobacterium leprae obtained from serial biopsies and by serum levels of phenolic glycolipid I. Clarithromycin was well tolerated, with only minor side effects noted in two patients. Most patients showed reductions in morphological index and radiorespirometry 1 week after the first two doses. Within 3 weeks of starting treatment (total of 17 g of clarithromycin), biopsy-derived M. leprae specimens from all patients had a morphological index of zero, were noninfectious for mice, and had less than 1% of the radiorespirometric activity of pretreatment specimens. Reductions in serum phenolic glycolipid I levels were observed for most patients at 3 weeks. Significant clinical improvement was evident after 4 weeks of treatment. All analyses indicate that clarithromycin is rapidly bactericidal for M. leprae in humans.
Full text
PDF


Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chan G. P., Garcia-Ignacio B. Y., Chavez V. E., Livelo J. B., Jimenez C. L., Parrilla M. L., Franzblau S. G. Clinical trial of sparfloxacin for lepromatous leprosy. Antimicrob Agents Chemother. 1994 Jan;38(1):61–65. doi: 10.1128/aac.38.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cho S. N., Cellona R. V., Fajardo T. T., Jr, Abalos R. M., dela Cruz E. C., Walsh G. P., Kim J. D., Brennan P. J. Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Int J Lepr Other Mycobact Dis. 1991 Mar;59(1):25–31. [PubMed] [Google Scholar]
- Chu S. Y., Sennello L. T., Bunnell S. T., Varga L. L., Wilson D. S., Sonders R. C. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother. 1992 Nov;36(11):2447–2453. doi: 10.1128/aac.36.11.2447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Franzblau S. G. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob Agents Chemother. 1989 Dec;33(12):2115–2117. doi: 10.1128/aac.33.12.2115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Franzblau S. G., Hastings R. C. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother. 1988 Dec;32(12):1758–1762. doi: 10.1128/aac.32.12.1758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gelber R. H., Fukuda K., Byrd S., Murray L. P., Siu P., Tsang M., Rea T. H. A clinical trial of minocycline in lepromatous leprosy. BMJ. 1992 Jan 11;304(6819):91–92. doi: 10.1136/bmj.304.6819.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gelber R. H., Murray L. P., Siu P., Tsang M. Clarithromycin at very low levels and on intermittent administration inhibits the growth of M. leprae in mice. Int J Lepr Other Mycobact Dis. 1992 Sep;60(3):485–487. [PubMed] [Google Scholar]
- Gelber R. H., Siu P., Tsang M., Murray L. P. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 1991 Apr;35(4):760–763. doi: 10.1128/aac.35.4.760. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
- Ji B., Jamet P., Perani E. G., Bobin P., Grosset J. H. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis. 1993 Jul;168(1):188–190. doi: 10.1093/infdis/168.1.188. [DOI] [PubMed] [Google Scholar]
- Ji B., Perani E. G., Grosset J. H. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 1991 Mar;35(3):579–581. doi: 10.1128/aac.35.3.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shepard C. C. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1982 Mar;50(1):96–101. [PubMed] [Google Scholar]